We are committed to restoring a healthy immune system for long term disease remission.

What We Do

Immune Regulation is a clinical stage biotech company, pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases.

Existing therapies are designed to suppress the immune system and require chronic dosing to treat the inflammation, frequently causing severe side effects.

Our first-in-class drug immune-resetting therapies have demonstrated unique efficacy and safety in preclinical and human studies without suppressing the immune system. These therapies exhibit a short pharmacokinetic activity but reset the immune system from a pro-inflammatory to a regulatory state to induce long-term disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies.

At Immune Regulation, our aim is to develop novel, safe and effective therapies that reset the immune system, transforming the lives of patients with inflammatory and immunological diseases.

 

 

Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies. (London UK and Boston USA, 21 September 2020) Immune Regulation Limited (“Immune Regulation”), a US and UK based clinical stage biotechnology company, today announced the closing of a Series B funding round led by Boston based Morningside […]

Read More